• Publications
  • Influence
Effects of intensive blood-pressure control in type 2 diabetes mellitus.
BACKGROUND There is no evidence from randomized trials to support a strategy of lowering systolic blood pressure below 135 to 140 mm Hg in persons with type 2 diabetes mellitus. We investigatedExpand
  • 2,721
  • 94
  • PDF
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
CONTEXT Secondary analyses of 2 randomized controlled trials and supportive epidemiologic and preclinical data indicated the potential of selenium and vitamin E for preventing prostate cancer. Expand
  • 1,818
  • 91
  • PDF
Effects of combination lipid therapy in type 2 diabetes mellitus.
BACKGROUND We investigated whether combination therapy with a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with type 2Expand
  • 2,152
  • 70
  • PDF
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
BACKGROUND In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein (LDL) cholesterol levels with statinExpand
  • 2,231
  • 69
  • PDF
Effects of intensive glucose lowering in type 2 diabetes.
BACKGROUND Epidemiologic studies have shown a relationship between glycated hemoglobin levels and cardiovascular events in patients with type 2 diabetes. We investigated whether intensive therapy toExpand
  • 4,661
  • 64
  • PDF
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
BACKGROUND Cardiovascular morbidity and mortality are higher among patients with type 2 diabetes, particularly those with concomitant cardiovascular diseases, than in most other populations. WeExpand
  • 1,270
  • 64
  • PDF
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
The British Regional Heart Study (BRHS) reported in 1986 that much of the inverse relation of high-density lipoprotein cholesterol (HDLC) and incidence of coronary heart disease was eliminated byExpand
  • 2,907
  • 57
  • PDF
Basal insulin and cardiovascular and other outcomes in dysglycemia.
BACKGROUND The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events, but such a possibility has not been formally tested. METHODS WeExpand
  • 1,231
  • 47
  • PDF
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
BACKGROUND We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS In this double‐blindExpand
  • 890
  • 40
  • PDF
Spironolactone for heart failure with preserved ejection fraction.
BACKGROUND Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction. We evaluated the effects of spironolactone inExpand
  • 930
  • 35
  • PDF